Incyte | INCY - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agenus USD 186.46M 40.34M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amgen USD 92.5B 1.92B 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
Exelixis USD 2.59B 250.83M 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
MacroGenics USD 217.87M 38.97M 2026-03
Merck USD 128.68B 8.18B 2026-03
Moderna USD 11.49B 850M 2026-03
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Novartis USD 110.95B 3.66B 2025-12
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03